SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Raises Price Target to $63

Cantor Fitzgerald reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $58 to $63.

Benzinga · 05/08/2020 11:05

Cantor Fitzgerald reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $58 to $63.